These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 1448780

  • 1. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2.
    Takiguchi Y, Wada K, Nakashima M.
    Thromb Haemost; 1992 Oct 05; 68(4):460-3. PubMed ID: 1448780
    [Abstract] [Full Text] [Related]

  • 2. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
    Takiguchi Y, Asai F, Wada K, Nakashima M.
    Thromb Haemost; 1995 Apr 05; 73(4):683-8. PubMed ID: 7495079
    [Abstract] [Full Text] [Related]

  • 3. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD, Müller TH.
    Basic Res Cardiol; 1997 Jun 05; 92(3):181-90. PubMed ID: 9226103
    [Abstract] [Full Text] [Related]

  • 4. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
    Horie S, Yamada M, Satoh M, Noritake S, Hiraishi S, Kizaki K, Kurusu O, Nakahara T, Ishii H, Kazama M.
    Biol Pharm Bull; 1997 Jun 05; 20(6):625-31. PubMed ID: 9212979
    [Abstract] [Full Text] [Related]

  • 5. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
    Matsuno H, Kozawa O, Nagashima S, Kanamaru M, Uematsu T.
    Br J Pharmacol; 1999 Jul 05; 127(5):1129-34. PubMed ID: 10455258
    [Abstract] [Full Text] [Related]

  • 6. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
    Umemura K, Kawai H, Ishihara H, Nakashima M.
    Jpn J Pharmacol; 1995 Mar 05; 67(3):253-8. PubMed ID: 7630043
    [Abstract] [Full Text] [Related]

  • 7. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
    White BP, Sullivan AT, Lumley P.
    Thromb Haemost; 1994 Mar 05; 71(3):366-74. PubMed ID: 8029802
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM, Valentin F, Tippins J, Kinsella BT, Masereel B, Pace-Asciak C, Pirotte B, Dogné JM.
    J Pharmacol Exp Ther; 2005 Apr 05; 313(1):293-301. PubMed ID: 15626721
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Depin JC, Vigié A, Chavernac G, Rousselot C, Lardy C, Guerrier D.
    Arzneimittelforschung; 1994 Nov 05; 44(11):1203-7. PubMed ID: 7848332
    [Abstract] [Full Text] [Related]

  • 10. [Comparative study of the antithrombotic effect of aspirin and Bay U3405, antagonist of a thromboxane A2 receptor].
    Cissé-Thiam M, Drouet L.
    Dakar Med; 1999 Nov 05; 44(1):25-7. PubMed ID: 10797981
    [Abstract] [Full Text] [Related]

  • 11. Evidence for a role in thrombus stabilization for thromboxane A2 in human platelet deposition on collagen.
    Wagner WR, Hubbell JA.
    J Lab Clin Med; 1992 Jun 05; 119(6):690-7. PubMed ID: 1534345
    [Abstract] [Full Text] [Related]

  • 12. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
    Matsuno H, Uematsu T, Umemura K, Takiguchi Y, Wada K, Nakashima M.
    Br J Pharmacol; 1992 Jul 05; 106(3):533-8. PubMed ID: 1387025
    [Abstract] [Full Text] [Related]

  • 13. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig.
    Hirata Y, Takiguchi Y, Wada K, Matsuno H, Umemura K, Uematsu T, Nakashima M.
    Eur J Pharmacol; 1993 Feb 16; 231(3):421-5. PubMed ID: 8449234
    [Abstract] [Full Text] [Related]

  • 14. Effects of the new thromboxane A2 antagonist vapiprost on isolated canine blood vessels.
    Matsuzaki T, Noguchi K, Nakasone J, Uezu K, Higuchi M, Sakanashi M.
    Arzneimittelforschung; 1992 Nov 16; 42(11):1318-22. PubMed ID: 1492844
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F, Colombo M, Pierucci L, Volpi D, Dho L, Ukmar G, Rosa B, Salvati P.
    Drugs Exp Clin Res; 1993 Nov 16; 19(6):249-60. PubMed ID: 8013268
    [Abstract] [Full Text] [Related]

  • 16. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C, Rousselot C, Chavernac G, Depin JC, Guerrier D.
    Arzneimittelforschung; 1994 Nov 16; 44(11):1196-202. PubMed ID: 7848331
    [Abstract] [Full Text] [Related]

  • 17. An experimental myocardial infarction model in the rat and its properties.
    Hirata Y, Umemura K, Uematsu T, Nakashima M.
    Jpn J Pharmacol; 1995 Jan 16; 67(1):51-7. PubMed ID: 7745845
    [Abstract] [Full Text] [Related]

  • 18. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S, Kawasaki T, Hisamichi N, Sakai Y, Taniuchi Y, Inagaki O, Yano S, Suzuki K, Terazaki C, Masuho Y, Satoh N, Takenaka T, Yanagi K, Ohshima N.
    Thromb Haemost; 1996 Apr 16; 75(4):679-84. PubMed ID: 8743199
    [Abstract] [Full Text] [Related]

  • 19. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
    Hornby EJ, Foster MR, McCabe PJ, Stratton LE.
    Thromb Haemost; 1989 Jun 30; 61(3):429-36. PubMed ID: 2529661
    [Abstract] [Full Text] [Related]

  • 20. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
    Azzam K, Cissé-Thiam M, Drouet L.
    Thromb Haemost; 1996 Jan 30; 75(1):203-10. PubMed ID: 8713802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.